<DOC>
	<DOCNO>NCT00161941</DOCNO>
	<brief_summary>The primary aim study show antibody response hepatitis B , acellular pertussis toxin inactivate poliovirus antigen 4th vaccination Hexavac® influence concomitant administration NeisVac-C .</brief_summary>
	<brief_title>Follow-up Study Antibody Response Hepatitis B , Acellular Pertussis Toxin Inactivated Poliovirus Antigens 1 Month After 4th Hexavac® Vaccination Healthy Children , Who Participated NeisVac-C Study 216</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>Study subject complete study 216 eligible participation study : receive 3 vaccination Hexavac study 216 4th Hexavac vaccination outside study subject 's parent ( ) /legal guardian ( ) understand study provide write informed consent his/her child 's study participation ; blood draw perform 3rd vaccination study 216 . Study subject exclude participation study : receive vaccination contain hepatitis B , poliovirus acellular pertussis toxin antigens Hexavac receive blood transfusion immunoglobulins period 28 day prior 4th Hexavac vaccination study entry receive another vaccine period 28 day prior 4th Hexavac vaccination study entry concurrently participate participate clinical trial investigational medicinal product since completion study 216 suffer disease ( e.g . autoimmune disease ) undergo form treatment may expect influence immunological function since completion study 216 receive systemic corticosteroid period 28 day prior 4th Hexavac vaccination study entry .</criteria>
	<gender>All</gender>
	<minimum_age>5 Months</minimum_age>
	<maximum_age>22 Months</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Meningococcal Vaccine</keyword>
	<keyword>Meningococcal Meningitis , Serogroup C</keyword>
	<keyword>Neisseria Meningitidis</keyword>
</DOC>